Nobligan (Tramadol Hydrochloride)

Tramadol works by binding to central μ‑opioid receptors, providing opioid‑type analgesia, and by inhibiting the reuptake of norepinephrine and serotonin. This dual action enhances descending pain‑inhibitory pathways, reducing the perception of pain.

The specific dose of Nobligan is determined by the prescribing clinician based on the patient’s pain severity, prior opioid exposure, age, renal and hepatic function, and other individual factors. Dosage adjustments are made to achieve effective pain control while minimizing adverse effects.

Safety data for tramadol during pregnancy and lactation are limited. Because potential risks to the fetus or infant cannot be excluded, the drug is generally avoided unless the expected benefit justifies the potential hazard. Consultation with a healthcare professional is essential.

To request Nobligan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with stronger opioids such as morphine, tramadol offers a lower risk of respiratory depression but has a unique serotonergic activity that can lead to serotonin syndrome when combined with certain drugs. Its analgesic potency is moderate, making it suitable for many pain scenarios where a full‑strength opioid may be excessive.

Nobligan tablets should be stored at ambient temperature, below 25 °C, in their original container to protect from moisture and light. Keep the product out of reach of children and do not use after the expiry date printed on the packaging.

Nobligan is taken orally, usually with a full glass of water. It may be taken with or without food, but consistent administration with respect to meals can help reduce gastrointestinal side effects. The exact schedule is set by the prescribing clinician.

Serious risks include respiratory depression, especially at high doses or when combined with other depressants; seizures in susceptible individuals; serotonin syndrome when used with serotonergic agents; and the potential for dependence, abuse, or withdrawal upon abrupt discontinuation.

Nobligan should be avoided in patients with known hypersensitivity to tramadol, those taking monoamine oxidase inhibitors, individuals with uncontrolled epilepsy, and patients with severe respiratory insufficiency. Caution is also advised for the elderly and for patients with significant renal or hepatic impairment.